Summary of a Workshop on the Role of Third-Party Payers in Clinical Trials of New Agents
Chalmers, Thomas C.
van den Noort, Stanley
Lockshin, Michael D.
Waksman, Byron H.
New England Journal of Medicine. 1983 Nov 24; 309(21): 1334-1336.
The Arthritis Foundation and the National Multiple Sclerosis Society sponsored a July 1983 workshop to explore methods of payment for clinical trials of expensive new therapies for the treatment of chronic disease. Participants included representatives of government agencies, private insurers, professional organizations, the pharmaceutical industry, HMOs, and voluntary agencies. The workshop recommended that the Health Care Financing Administration fund clinical trials; that Blue Cross/Blue Shield and other private insurers identify a category of treatment methods as "investigative" or "under evaluation," to be reimbursed for patients participating in approved trials; that the National Institutes of Health take a larger role in clinical trials if funding is forthcoming; that consideration be given to creating a technology assessment entity to carry out therapeutic trials; and that the Institute of Medicine appoint a committee to monitor progress toward these goals. (KIE abstract)
Biomedical Technologies; Chronically Ill; Clinical Trials; Disease; Drug Industry; Drugs; Evaluation; Federal Government; Financial Support; Goals; Government; Government Financing; Health; Health Care; Health Insurance; Human Experimentation; Industry; Insurance; Medicine; Methods; Organizations; Patients; Professional Organizations; Public Policy; Pharmaceutical Industry; Random Selection; Technology; Technology Assessment;
Showing items related by title, author, creator and subject.
Iltis, Ana S. (2005-06)Four principal arguments have been offered in support of requiring public and private third-party payers to help fund medical research: (1) many of the costs associated with clinical trial participation are for routine ...